Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 33.56% is in line with its 5-year average of 30.57%, near the high end of its 5-year range (26.69%–35.15%).
1.49% above its 12-month average of 33.07%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 35.15%.
GROSS MARGIN
33.56%
GROSS MARGIN AVG TTM
33.07%
GROSS MARGIN AVG 3Y
32.13%
GROSS MARGIN AVG 5Y
30.57%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.49%
CURRENT VS 3Y AVG
+4.45%
CURRENT VS 5Y AVG
+9.79%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.63%
median of 782 covered companies
CURRENT VS SECTOR MEDIAN
-17.40%
vs the sector median at left
LifeStance Health Group, Inc.
Market Cap
$4.67B
Gross Margin
33.56%
TTM Avg
33.07%
3Y Avg
32.13%
5Y Avg
30.57%
Market Cap
$4.66B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.66B
Gross Margin
18.17%
TTM Avg
19.16%
3Y Avg
20.78%
5Y Avg
21.38%
Market Cap
$4.71B
Gross Margin
96.01%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$4.63B
Gross Margin
71.27%
TTM Avg
60.67%
3Y Avg
48.49%
5Y Avg
48.49%
Market Cap
$4.82B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.85B
Gross Margin
81.70%
TTM Avg
78.24%
3Y Avg
78.79%
5Y Avg
67.54%
Market Cap
$4.43B
Gross Margin
80.08%
TTM Avg
75.94%
3Y Avg
72.82%
5Y Avg
72.82%
Market Cap
$4.41B
Gross Margin
75.44%
TTM Avg
66.98%
3Y Avg
64.58%
5Y Avg
67.25%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeStance Health Group, Inc. (LFST) | $4.67B | 33.56% | 33.07% | 32.13% | 30.57% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.66B | 0.00% | 0.00% | 0.00% | 0.00% |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 18.17% | 19.16% | 20.78% | 21.38% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.71B | 96.01% | 100.00% | 100.00% | 83.33% |
| BillionToOne, Inc. (BLLN)vs › | $4.63B | 71.27% | 60.67% | 48.49% | 48.49% |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.82B | 0.00% | 0.00% | 0.00% | 0.00% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.85B | 81.70% | 78.24% | 78.79% | 67.54% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | 80.08% | 75.94% | 72.82% | 72.82% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | 75.44% | 66.98% | 64.58% | 67.25% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | 83.86% | 80.36% | 82.01% | 82.83% |
Gross Margin
33.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 35.15% |
| 2026-03-31 | 33.69% |
| 2025-12-31 | 33.04% |
| 2025-09-30 | 32.04% |
| 2025-06-30 | 31.40% |
| 2025-03-31 | 32.97% |
| 2024-12-31 | 33.62% |
| 2024-09-30 | 32.12% |
| 2024-06-30 | 31.31% |
| 2024-03-31 | 31.53% |
| 2023-12-31 | 29.69% |
| 2023-09-30 | 28.99% |
| 2023-06-30 | 28.11% |
| 2023-03-31 | 27.56% |
| 2022-12-31 | 27.33% |
| 2022-09-30 | 27.71% |
| 2022-06-30 | 28.55% |
| 2022-03-31 | 26.69% |
| 2021-12-31 | 28.55% |
| 2021-09-30 | 29.94% |
| 2021-06-30 | 31.90% |
| 2021-03-31 | 30.74% |
| 2020-12-31 | 33.00% |
| 2020-09-30 | 32.49% |
| 2020-06-30 | 31.19% |
| 2020-03-31 | 29.37% |
